003060.KS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 04:18):

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs...

Stats
Šios dienos apimtis	33 651.00
Vidutinė apimtis	882 414
Rinkos kapitalizacija	104.15B
EPS	KRW0 ( 2024-03-15 )
Kita pelno data	( KRW0 ) 2024-05-10
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW1.610 (0.10%)

Tūris Koreliacija

Ilgas: 0.01 (neutral)

Trumpas: -0.03 (neutral)

Signal:(73.547) Neutral

Aprogen Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aprogen Koreliacija - Valiuta/Žaliavos

-0.16
( neutral )

-0.12
( neutral )

0.14
( neutral )

-0.29
( neutral )

-0.51
( weak negative )

-0.35
( neutral )

Aprogen Finansinės ataskaitos

Annual	2023
Pajamos:	KRW87.36B
Bruto pelnas:	KRW-12.05B (-13.79 %)
EPS:	KRW-187.48

FY	2023
Pajamos:	KRW87.36B
Bruto pelnas:	KRW-12.05B (-13.79 %)
EPS:	KRW-187.48

FY	2022
Pajamos:	KRW65.19B
Bruto pelnas:	KRW27.29B (41.86 %)
EPS:	KRW13.81

FY	2021
Pajamos:	KRW56.48B
Bruto pelnas:	KRW25.44B (45.05 %)
EPS:	KRW25.52

Financial Reports:

No articles found.

Aprogen

Aprogen pharmaceuticals,Inc. manufactures and sells pharmaceutical products primarily in South Korea. It offers approximately 200 types of medicines, including ethical and over the counter drugs. The company offers its drugs for transfusion, digestive system, osteoarthritis, skeletal muscle relaxants, NSAIDs, osteoporosis, circulatory system, endocrine, respiratory system, urinary system, depilatory, antihistamines and antiallergics, obesity, brain function, neurologics, and male pattern hair loss. It also provides anti-biotic, anti-fungal, anti-viral, anti-ulcerant, anti-epliepsy products; external agents; anti-cancer drugs; amino-acid nutrient transfusion agents; and cosmetics. The company was formerly known as Schnell Biopharmaceuticals, Inc. and changed its name to Aprogen pharmaceuticals,Inc. in April 2017. Aprogen pharmaceuticals,Inc. was founded in 1960 and is headquartered in Seongnam, South Korea.